Table 4.

Metaregression to Examine the Impact of Potential Modifiers on the Effects of Obstructive Sleep Apnea Syndrome on FMD, NTG‐Induced Dilation, cfPWV, CRP/hsCRP, and TNF‐α

Metaregression Variables	FMD		NTG‐Induced Dilation		cfPWV		CRP/hsCRP		TNF‐α
	Exp (b)	P Value	Exp (b)	P Value	Exp (b)	P Value	Exp (b)	P Value	Exp (b)	P Value
Mean age	0.965	0.396	1.086	0.309	0.969	0.611	1.013	0.591	1.063	0.857
BMI	0.804	0.003a	0.845	0.479	1.429	0.126	0.960	0.425	0.978	0.900
Male sex	1.024	0.250	NE	NE	1.018	0.241	1.012	0.189	1.058	0.220
SBP	1.062	0.315	1.191	0.370	0.931	0.197	1.029	0.870	1.039	0.934
DBP	1.081	0.065	0.708	0.346	1.026	0.669	0.970	0.678	1.423	0.643
Smoke	1.002	0.955	0.921	0.391	1.026	0.288	No	No	NE	NE
TC	1.004	0.685	1.019	0.321	1.016	0.700	0.984	0.391	No	No
TG	1.015	0.030a	NE	NE	0.983	0.591	0.998	0.529	No	No
FBG	1.022	0.540	0.972	0.547	1.017	0.592	0.999	0.791	No	No
HDL	1.015	0.840	NE	NE	1.051	0.831	1.280	0.603	No	No
LDL	NE	NE	NE	NE	NE	NE	NE	NE	No	No
HR	No	No	No	No	NE	NE	NE	NE	NE	NE
EES	NE	NE	No	No	No	No	0.917	0.567	1.491	0.795
Publication year	0.934	0.529	1.035	0.810	0.870	0.325	1.017	0.606	1.154	0.582

Exp(b) is the value of the risk ratio of continuous variables. BMI indicates body mass index (kg/m²); cfPWV, carotid‐femoral pulse wave velocity (m/s); CRP, C‐reactive protein; DPB, diastolic blood pressure (mm Hg); EES, Epworth sleepiness score; FBG, fasting blood glucose (mg/dL); FMD, flow‐mediated dilatation (%); HDL, high‐density lipoprotein (mg/dL); HR, heart rate (beats per minute); hsCRP, high‐sensitivity C‐reactive protein (mg/dL); LDL, low‐density lipoprotein (mg/dL); NE, not enough studies; No, no study reported the covariate; NTG, nitroglycerin; OSAS, obstructive sleep apnea syndrome; SBP, systolic blood pressure (mm Hg); TC, total cholesterol (mg/dL); TG, triglycerides (mg/dL); TNF‐α, tumour necrosis factor‐α (pg/mL).

^a P<0.05.